A robust immunohistochemical assay for detecting pten expression in human tumors

Applied Immunohistochemistry and Molecular Morphology

Volumn 19, Issue 2, 2011, Pages 173-183

  Sangale, Zaina ^a   Prass, Cynthia ^a   Carlson, Amy ^a   Tikishvili, Eliso ^a   Degrado, Jorja ^b   Lanchbury, Jerry ^a   Stone, Steven ^a  

^a Myriad Genetic Laboratories   (United States)

^b ARUP LABORATORIES   (United States)

Author keywords

IHC; PREZEON; PTEN

Indexed keywords

ANTIBODY; FORMALDEHYDE; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; PARAFFIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ARTICLE; ASSAY; AUTOMATION; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CERTIFICATION; COLON; COLON ADENOCARCINOMA; CONTROLLED STUDY; COPY NUMBER VARIATION; ENDOMETRIUM CANCER; ENDOMETRIUM CELL; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABORATORY; LUNG ADENOCARCINOMA; LUNG PARENCHYMA; PATHOLOGIST; PERIPHERAL NERVE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; REPRODUCIBILITY; SCORING SYSTEM; STAINING; VALIDATION STUDY;

ANTIBODIES; BIOLOGICAL ASSAY; CELL LINE, TUMOR; ENDOTHELIAL CELLS; FEMALE; GENE DOSAGE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASMS; PARAFFIN EMBEDDING; PERIPHERAL NERVES; PTEN PHOSPHOHYDROLASE; TISSUE FIXATION; TUMOR MARKERS, BIOLOGICAL;

EID: 79951958340     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3181f1da13     Document Type: Article

References (39)

1. Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997;15:356-362. (Pubitemid 27147102)
2. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci. 1999;96:4240-4245. (Pubitemid 29190320)
3. Das S, Dixon JE, Cho W. Membrane binding and activation mechanism of PTEN. Proc Natl Acad Sci. 2003;100:7491-7496. (Pubitemid 36759997)
4. Fanning AS, Anderson JM. Protein modules as organizers of membrane structure. Curr Opin Cell Biol. 1999;11:432-439. (Pubitemid 29396788)
5. Gimm O, Perren A, Weng LP, et al. Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and in benign and malignant epithelial thyroid tumors. Am J Pathol. 2000; 156:1693-1700. (Pubitemid 30646707)
6. Maehama T, Dixon JE. The tumor suppressor PTEN/MMAC1, dephosphorylates the lipid second messenger phosphoinositol 3,4,5- triphosphate. J Biol Chem. 1998;273:13375-13378.
7. Li DM, Sun H. PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci. 1998;95:15406-15411. (Pubitemid 29018711)
8. Risinger J, Hayes AK, Berchuck A, et al. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res. 1997;57:4736-4738. (Pubitemid 27468978)
9. Teng DH, Hu R, Lin H, et al. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res. 1997;57: 5221-5225. (Pubitemid 27516352)
10. Gray IC, Stewart LM, Phillips SM, et al. Mutation and expression analysis of the putative prostate tumor suppressor gene PTEN. Br J Cancer. 1998;78:1296-1300. (Pubitemid 28495240)
11. Dicuonzo G, Angeletti S, Garcilla-Foncillas J, et al. Colorectal carcinoma and PTEN/MMAC1 gene mutations. Clin Cancer Res. 2001;7:4049-4053. (Pubitemid 34044626)
12. Obata K, Morland SJ, Watson RH, et al. Frequent PTEN/MMAC1 mutations in endometrioid but not in serous or mucinous ovarian cancer. Cancer Res. 1998;58:2095-2097. (Pubitemid 28232892)
13. Alimov A, Li C, Gizatullin R, et al. Somatic mutation and homozygous deletion of PTEN/MMAC1 gene of 10q23 in renal cell carcinoma. Anticancer Res. 1999;19:3841-3846.
14. Yoshimoto M, Cunha IW, Coudry RA, et al. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer. 2007;97:678-685. (Pubitemid 47339893)
15. Bedolla R, Prihoda TJ, Kreisberg JI, et al. Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin Cancer Res. 2007;13:3860-3867. (Pubitemid 47037592)
16. Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007;12: 395-402. (Pubitemid 47539306)
17. Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004;6:117-127. (Pubitemid 39485684)
18. Faratian D, Goltsov A, Lebedeva G, et al. Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab. Cancer Res. 2009;69: 6713-6720.
19. Frattini M, Saletti P, Romagnani E, et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer. 2007;97:1139-1145. (Pubitemid 47587019)
20. Sartore-Bianchi A, DiNicholantonio F, Nichelatti M, et al. Multideterminants analysis of molecular alterations predicting clinical benefit to EGFR targeted monoclonal antibodies in colorectal cancer. PLoS One. 2009;4:e728
21. Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from Cetuximab therapy in wild type KRAS metastatic colon cancer. J Clin Oncol. 2009;35:5924-5930.
22. Noro R, Gemma A, Miyanaga A, et al. PTEN inactivation in lung cancer and the effect of its recovery on treatment with epidermal growth factor tyrosine kinase inhibitors. Int J Oncol. 2007;31: 1157-1163.
23. Sos ML, Koker M, Weir BA, et al. PTEN loss contributes to erlotinib resistance in EGFR mutant lung cancer by activation of Akt and EGFR. Cancer Res. 2009;69:3256-3261.
24. Birck A, Ahrenkeil V, Zeuthen J, et al. Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies. J Invest Dermatol. 2000;114:277-280. (Pubitemid 30417761)
25. Sircar K, YoshimotoM,Monzon FA, et al. PTENgenomic deletion is associated with p-Akt and AR signaling in poorer outcome hormone refractory prostate cancer. J Pathol. 2009;218:505-513.
26. Bose S, Wang SI, Terry MB, et al. Allelic loss of chromosome 10q23 is associated with tumor progression in breast cancer. Oncogene. 1998;17:123-127. (Pubitemid 28360536)
27. Perren A, Weng LP, Boag AH, et al. Immunohistochemcial evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol. 1999;155:1253-1260. (Pubitemid 29488932)
28. Terakawa N, Kanamori Y, Yoshida S. Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. Endocrine-Related Cancer. 2003;10: 203-208. (Pubitemid 36758649)
29. Tantbirojn P, Triratanachat S, Trivijitsilp P, et al. Detection of PTEN immunoreactivity in endometrial hyperplasia and adenocarcinoma. J Med Assoc Thai. 2008;91:1161-1165.
30. Sassen A, Diermeier-Daucher S, Sieben M, et al. Presence of HER4 associates with increased sensitivity to Herceptint in patients with metastatic breast cancer. Breast Cancer Res. 2009; 11:R50.
31. Wiencke JK, Zheng S, Jelluma N, et al. Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. Neuro Oncol. 2007;9:271-279. (Pubitemid 47169659)
32. Lee C, Kim JS, Waldman T. PTEN gene targeting reveals a radiation induced size checkpoint in human cancer cells. Cancer Res. 2004;64:6906-6914. (Pubitemid 39330998)
33. Abkevitch V, Illiev D, Timms K, et al. Computational method for estimating DNA copy numbers in normal samples, cancer cell lines, and solid tumors using array comparative genomic hybridization. J Biomed Biotech. 2010. doi:10.1155/2010/386870.
34. Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53- mediated G1 arrest in human cancer cells. Cancer Res. 1995;55: 5187-5190.
35. Li J, Simpson L, Takahashi M, et al. The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the Akt/protein kinase B oncogene. Cancer Res. 1998;58:5667-5672. (Pubitemid 29006402)
36. Perren A, Komminoth P, Saremaslani P, et al. Mutation and expression analysis reveals differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol. 2000;157:1097-1103.
37. Gimm O, Perren A, Weng L, et al. Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue and in benign and malignant epithelial thyroid tumors. Am J Pathol. 2000; 156:1693-1700. (Pubitemid 30646707)
38. Ginn-Pease ME, Eng C. Increased nuclear phosphatase and tensin homologue deleted on chromosome 10 is associated with G0-G1 in MCF-7 cells. Cancer Res. 2003;63:282-286. (Pubitemid 36152480)
39. Mori S, Ito G, Usami N, et al. p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma. Cancer. 2004;100:1673-1682. (Pubitemid 38456345)